VENTANA PTEN (SP218) RxDx Assay
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Immunohistochemistry Assay, Antibody · Pathology
Open FDA's page for this record- PMA number
- P250031
- Applicant
- Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)
- Street 1
- 1910 E. Innovation Park Dr.
- City
- Tucson
- State
- AZ
- Zip
- 85755
- Generic name
- Immunohistochemistry Assay, Antibody
- Trade name
- VENTANA PTEN (SP218) RxDx Assay
- Product code
- SHF
- Advisory committee
- PA
- Advisory committee description
- Pathology
- Expedited review flag
- N
- Date received
- 2025-08-18
- Decision date
- 2026-06-12
- Docket number
- 26M-6735
- Fed reg notice date
- 2026-06-12
- Decision code
- APPR
- Ao statement
VENTANA PTEN (SP218) RxDx Assay is a qualitative immunohistochemical (IHC) assay using rabbit monoclonal anti-PTEN, clone SP218, intended for laboratory use in the assessment of phosphatase and tensin homolog (PTEN) protein in formalin-fixed paraffin-embedded (FFPE) prostatic adenocarcinoma tissue specimens by light microscopy. The assay is for use with OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument. The assay is indicated as a companion diagnostic to aid in identifying patients who may be eligible for treatment with TRUQAP (capivasertib) in combination with abiraterone acetate in accordance with the approved therapeutic product labeling. The clinical cutoff for PTEN Loss status is >=90% of viable malignant cells with no specific cytoplasmic staining.Test results should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This product is intended for in vitro diagnostic (IVD) use.
- Harmonized identifiers (openFDA)
- Registration number
- 2028492
- FEI number
- 1000125183
